These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 149588)

  • 1. Lymphocyte transformation in patients with staged mycosis fungoides and Sézary syndrome.
    du Vivier A; Harper RA; Vonderheid E; Van Scott EJ
    Cancer; 1978 Jul; 42(1):209-13. PubMed ID: 149588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--part II.
    Safai B
    Clin Bull; 1977; 7(4):140-5. PubMed ID: 147147
    [No Abstract]   [Full Text] [Related]  

  • 3. Current problems in mycosis fungoides and Sézary syndrome.
    Winkelmann RK; Caro WA
    Annu Rev Med; 1977; 28():251-69. PubMed ID: 140621
    [No Abstract]   [Full Text] [Related]  

  • 4. Surface markers and mitogen response of cells harvested from cutaneous infiltrates in mycosis fungoides and Sézary's syndrome.
    Burg G; Rodt H; Grosse-Wilde H; Braun-Falco O
    J Invest Dermatol; 1978 May; 70(5):257-9. PubMed ID: 147911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell characterization in mycosis fungoides.
    Robinowitz BN; Noguchi S; Roenigk HH
    Cancer; 1976 Apr; 37(4):1747-53. PubMed ID: 1083287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
    Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
    Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sézary cell count in exfoliative dermatitis.
    Duangurai K; Piamphongsant T; Himmungnan T
    Int J Dermatol; 1988 May; 27(4):248-52. PubMed ID: 2968960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
    Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
    J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of functional immunoregulatory cells in a patient with mycosis fungoides and circulating Sézary cells.
    Kermani-Arab V; Roberts JL; Hanifin JM; Leslie GA
    J Natl Cancer Inst; 1978 Jun; 60(6):1295-9. PubMed ID: 148516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunological profile of mycosis fungoides.
    Jensen JR; Thestrup-Pedersen K; Ahrons S; Zachariae H
    Clin Exp Immunol; 1982 Nov; 50(2):397-405. PubMed ID: 6983938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage inhibitor factor (MIF) in cutaneous lymphoproliferative diseases.
    Umbert P; Belcher RW; Winkelmann RK
    Br J Dermatol; 1976 Nov; 95(5):475-80. PubMed ID: 136265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymus-dependent lymphocytes in lymphoproliferative disorders of the skin (Sézary syndrome and mycosis fungoides).
    Zucker-Franklin D
    J Invest Dermatol; 1976 Sep; 67(3):412-8. PubMed ID: 135031
    [No Abstract]   [Full Text] [Related]  

  • 13. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
    Sentis HJ; Willemze R; Scheffer E
    J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders.
    Lutzner M; Edelson R; Schein P; Green I; Kirkpatrick C; Ahmed A
    Ann Intern Med; 1975 Oct; 83(4):534-52. PubMed ID: 126656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T and B cells and cell-mediated immunity in mycosis fungoides.
    Nordqvist BC; Kinney JP
    Cancer; 1976 Feb; 37(2):714-8. PubMed ID: 130203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified staging classification for cutaneous T-cell lymphoma.
    Kashani-Sabet M; McMillan A; Zackheim HS
    J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructural, immunologic, and functional studies on Sézary cells: a neoplastic variant of thymus-derived (T) lymphocytes.
    Zucker-Franklin D; Melton JW; Quagliata F
    Proc Natl Acad Sci U S A; 1974 May; 71(5):1877-81. PubMed ID: 4275944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG anti-50 kd lymphocyte membrane peptide antibody in patients with Sézary syndrome.
    D'Ambra-Cabry K; Tharp MD; Jagasothy BV; Deng JS
    J Am Acad Dermatol; 1996 May; 34(5 Pt 1):777-80. PubMed ID: 8632073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sézary syndrome. Clinical, immunological and proliferative kinetics].
    Marosi L; Hofer F; Schwarzmeier J; Konrad K; Knapp W; Radaskiewicz T
    Acta Med Austriaca; 1979; 6(5):237-40. PubMed ID: 318012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.